Collegium Pharmaceutical Stock Price, News & Analysis (NASDAQ:COLL)

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. The specialty pharmaceutical company had revenue of $75.04 million for the quarter, compared to analyst estimates of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. Collegium Pharmaceutical's quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the firm posted ($0.40) EPS. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

6 brokerages have issued 12 month target prices for Collegium Pharmaceutical's stock. Their predictions range from $22.00 to $33.00. On average, they expect Collegium Pharmaceutical's stock price to reach $26.20 in the next year. This suggests a possible upside of 126.6% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Press coverage about COLL stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a decrease in short interest in September. As of September 15th, there was short interest totalling 2,810,000 shares, a decrease of 7.0% from the August 15th total of 3,020,000 shares. Based on an average daily volume of 275,600 shares, the days-to-cover ratio is presently 10.2 days. Approximately 10.1% of the shares of the company are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Opko Health (OPK), Madrigal Pharmaceuticals (MDGL), Eidos Therapeutics (EIDX), Radius Health (RDUS), BELLUS Health (BLUSF), Zymeworks (ZYME), Enanta Pharmaceuticals (ENTA), Turning Point Therapeutics (TPTX), ArQule (ARQL), Innoviva (INVA) and Endo International (ENDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), Celgene (CELG), NVIDIA (NVDA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.03%), Nisa Investment Advisors LLC (0.03%) and Meeder Asset Management Inc. (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $11.56.

Collegium Pharmaceutical has a market capitalization of $386.91 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.